Valentina Cirello
Milan, 20122, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Development of a sensitive plasma lenvatinib quantification method and validation in thyroid cancer patients.
Journal: Journal of the Endocrine Society
Published: April 09, 2026
Patient-Derived in Vitro Models Reveal Insights into Medullary Thyroid Cancer Microenvironment and Resistance to Tyrosine Kinase Inhibitors.
Journal: Thyroid : official journal of the American Thyroid Association
Published: February 06, 2026
The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function.
Journal: Frontiers in endocrinology
Published: November 10, 2025
TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer.
Journal: The Journal of clinical endocrinology and metabolism
Published: September 20, 2024
Thyroid cancer and endocrine disruptive chemicals: a case-control study on per-fluoroalkyl substances and other persistent organic pollutants.
Journal: European thyroid journal
Published: September 18, 2023
Correction: Fetal cell microchimerism and susceptibility to COVID-19 disease in women.
Journal: Infection
Published: May 11, 2023
Fetal cell microchimerism and susceptibility to COVID-19 disease in women.
Journal: Infection
Published: November 21, 2022
Oxidative Stress Correlates with More Aggressive Features in Thyroid Cancer.
Journal: Cancers
Published: October 31, 2022
Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report.
Journal: Frontiers in oncology
Published: May 20, 2022
Tissue sensitivity to thyroid hormones may change over time.
Journal: European thyroid journal
Published: January 03, 2022
FAM83B is involved in thyroid cancer cell differentiation and migration.
Journal: Scientific reports
Published: November 16, 2021
Last Updated: 09/26/2026